Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | KRAS | P01116 | 1/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052289 | 0.97 | DPP3 (0.59) | DPP3DPP4 | |
| SCHEMBL30051339 | 0.96 | DPP4 (0.58) | DPP3DPP4KRASSOS1 | |
| SCHEMBL29666786 | 0.95 | DPP3 (0.59) | DPP3DPP4OPRM1 | |
| SCHEMBL30432327 | 0.92 | DPP3 (0.55) | DPP3 | |
| SCHEMBL30311085 | 0.91 | DPP4 (0.56) | DPP3DPP4KRASSOS1 | |
| SCHEMBL31475666 | 0.90 | CCKBR (0.54) | DPP3 | |
| SCHEMBL29829082 | 0.90 | DPP4 (0.54) | DPP3DPP4KRASSOS1 | |
| SCHEMBL30051839 | 0.90 | DPP4 (0.54) | DPP3DPP4KRASSOS1 | |
| SCHEMBL29966903 | 0.90 | DPP4 (0.54) | DPP3DPP4 | |
| SCHEMBL30311056 | 0.88 | DPP3 (0.52) | DPP3DPP4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-121758548-A | Bioactive peptide in low-grade tobacco leaves, screening preparation and application thereof | 云南省烟草公司玉溪市公司 | 2026-03-31 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | DPP3 25/4885DPP4 43/4885OPRM1 804/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | DPP3 64/4885DPP4 73/4885OPRM1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.